Table 2. Cost input.
| Costs (US dollars) Parameter | Base-case value | Range | Description | Reference |
|---|---|---|---|---|
| Cost of pemetrexed per 500 mg | 2083.97 | 857.14–2126.51 | Local charge | |
| Cost of traditional chemotherapy per cycle other than pemetrexed | 518.4 | 388.8–648 | Local charge | |
| Cost of crizotinib per day | 238.1 | 119.05–238.1* | Local charge | |
| Cost of follow-up per unit | 55.6 | 41.7–69.4 | Wu et al., 2014 | |
| Cost of salvage chemotherapy per cycle | 2352.7 | 1921.1–4383.3 | Wu et al., 2014 | |
| Cost of palliative care in end-of-life | 2042.91 | 793.65–5456.19 | Lu et al., 2016(2) | |
| Cost of supportive care per cycle | 337.5 | 158.7–793.7 | Wu et al., 2014 | |
| Cost of SAEs in initial chemotherapy per cycle | 507.4 | 189.7–825.0 | Wu et al., 2014 | |
| Cost of ALK rearrangement testing | ||||
| NGS | 1,014.49 | 869.57–1,159.42 | Local charge | |
| Multiplex PCR | 660.75 | 440.50–881.01 | Local charge |
* The half of expense of crizotinib was assumed for the one-way sensitivity analysis.
NGS: next-generation sequencing; PCR: polymerase chain reaction